Philips CEO Frans van Houten. Picture: EVA PLEVIER/REUTERS
Philips CEO Frans van Houten. Picture: EVA PLEVIER/REUTERS

Amsterdam  — Philips shares plunged more than 11% on Wednesday after the Dutch health technology company hiked the cost of its massive recall of ventilators and said earnings would take a big hit from global supply chain shortages.

The supplier of hospital equipment and personal health devices said it expected fourth-quarter core profit to drop almost 40% to about €650m, as it continued to scramble for memory chips and other parts.

“It's a difficult situation,” CEO Frans van Houten said. “We had shortages of several components and saw port congestion, sometimes between two to three weeks. All of this meant our manufactured goods couldn’t reach customers in time.”

Comparable sales fell 10% on a yearly basis to €4.9bn, Philips said, as hospitals had to postpone the installation of equipment due to a lack of parts.

Van Houten said the supply chain problems had intensified over the fourth quarter, and were not expected to disappear in the first months of 2022. But he maintained guidance that growth would resume over the course of the year.

Quarterly sales were around €350m lower than Philips had expected, taking comparable sales over 2021 down 1%, versus the company’s previous guidance for a small rise.

The adjusted margin on earnings before interest, tax and amortisation (ebita) is now expected to fall to about 12% from 13.2% in 2020, against a previous forecast for a modest rise.

The supply chain problems added to worries over the recall of ventilators, which has spooked investors and lopped over 18 billion euros of the Amsterdam-based company's market value over the past nine months.

Philips said it had taken a new provision of €225m as it expected to take back and repair over 1-million more devices than previously anticipated.

This took total costs of the recall to €725m.

That amount, however, does not cover the possible costs of litigation, with Philips facing more than a hundred class action suits from worried patients, some of whom have alleged degrading foam in the devices could cause cancer or other health issues.

In 2021, the company estimated it would replace up to 4-million ventilators and respiratory devices worldwide because of a polyurethane foam part that might degrade and become toxic.

In December, it said first tests on impacted devices had shown encouraging results, indicating the problem would not result in long-term health consequences for patients.

The company will publish full quarterly and yearly results on January 24.

Reuters 

subscribe

Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.